Fair Observer Publishes Editorial Calling for Medical Cannabis Legalization

Editorial Advocates Federal Rescheduling

The Fair Observer editorial joins a wave of policy commentary urging Congress to reconcile the 38-state medical cannabis framework with federal prohibition. It went live on the platform's website June 14, 2026, according to Google News aggregation data. Fair Observer is an international news analysis site based in California. It publishes opinion and analysis on global policy issues.

The editorial's timing coincides with ongoing congressional debate over the placement of cannabis in Schedule III of the Controlled Substances Act, a reclassification proposed by the Department of Justice in 2024 but not yet finalized. Schedule III status would recognize accepted medical use but maintain federal controls and preserve IRC §280E tax burdens for state-licensed operators.

38 States Operate Medical Programs Under Federal Conflict

Thirty-eight states and the District of Columbia have enacted medical marijuana statutes, creating a direct conflict with the federal Controlled Substances Act's Schedule I classification. On a strict reading of 21 U.S.C. §812(b)(1), Schedule I substances have no accepted medical use. They can't be prescribed. Yet state medical programs rely on physician certifications to authorize patient access.

This conflict has operational consequences. State-licensed medical dispensaries can't deduct ordinary business expenses under IRC §280E because they traffic in a Schedule I substance. The Internal Revenue Service has consistently applied 280E to medical operators, even in states with comprehensive regulatory frameworks. The effective tax rate for these businesses often exceeds 70 percent of gross profit.

The federal-state conflict forces medical operators into a permanent tax penalty, regardless of state compliance, because the Controlled Substances Act classification controls federal tax treatment.

Rescheduling Doesn't Resolve Tax or Banking Access

Moving cannabis to Schedule III would eliminate the 280E tax penalty but wouldn't grant state operators access to federal banking services or interstate commerce. Schedule III substances remain controlled under the CSA. Banks operating under federal charters would still face potential prosecution for aiding and abetting violations of 21 U.S.C. §841, the distribution statute.

The SAFER Banking Act passed the House in 2023 but stalled in the Senate. It hasn't been reintroduced in the current Congress. Without it, rescheduling alone doesn't open correspondent banking relationships or credit-card processing for medical dispensaries.

What to Watch: Congressional Action on Scheduling and Banking

The next legislative signal will be whether the Senate takes up a companion to any House-passed cannabis banking bill in the 119th Congress. The Fair Observer editorial reflects public pressure on lawmakers to act. Opinion pieces don't move the legislative calendar.

For operators, the relevant variables remain: (1) finalization of the DEA's Schedule III rulemaking, expected in late 2026 or early 2027; (2) passage of banking safe-harbor legislation; and (3) any effort to deschedule cannabis entirely, which would require amending the Controlled Substances Act. For full background on the federal rescheduling process, see the CannIntel topic hub on medical marijuana legalization.